Noteworthy ETF Inflows: DFAC, CVX, WFC, MRK
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2025
0mins
Should l Buy MRK?
Source: NASDAQ.COM
DFAC Stock Performance: DFAC's stock has a 52-week range with a low of $28.39 and a high of $36.66, currently trading at $34.37, which is useful for technical analysis when compared to the 200-day moving average.
ETFs Trading Dynamics: Exchange traded funds (ETFs) operate like stocks but involve buying and selling units that can be created or destroyed based on investor demand, impacting the underlying holdings significantly during notable inflows or outflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 115.680
Low
95.00
Averages
119.53
High
139.00
Current: 115.680
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MERCK & CO INC ANTICIPATES $5.8 BILLION CHARGE OF APPROXIMATELY $2.35 PER SHARE IN Q2 AND FY2026, WITH DEAL CLOSURE EXPECTED IN Q2 2026
Merck & Co. Deal Closure: Merck & Co. is expected to finalize a significant deal in the second quarter of 2026.
Financial Implications: The deal is projected to incur a charge of approximately $2.35 per share in the second quarter and will impact the financial results for the fiscal year 2026.
See More
MERCK & CO INC - TRANSACTION VALUED AT APPROXIMATELY $5.7 BILLION NET OF CASH, REFLECTING A 31% PREMIUM OVER 60-DAY VWAP AS OF MARCH 24, 2026
- Deal Overview: Merck & Co has announced a deal valued at approximately $5.7 billion.
- Premium Details: The deal includes a 31% premium based on the 60-day volume-weighted average price (VWAP) as of March 24, 2026.
See More
Merck & Co Inc Acquires Terns Pharmaceuticals at $53.00 Per Share, Valuing Equity at $6.7 Billion
- Acquisition Announcement: Merck & Co. has announced its intention to acquire Terns Pharmaceuticals for $53.00 per share.
- Valuation Details: The total equity value of the acquisition is estimated at $6.7 billion.
See More
Merck to Purchase Terns Pharmaceuticals, Enhancing Hematology Pipeline with TERN-701, a New Treatment for Chronic Myeloid Leukemia (CML)
Merck's Acquisition: Merck has acquired Terns Pharmaceuticals, Inc. to enhance its hematology pipeline.
Focus on Chronic Myeloid Leukemia: The acquisition includes Terns' novel candidate, TERN-701, which is aimed at treating chronic myeloid leukemia (CML).
See More
MERCK CLOSES IN ON $6BN BIOTECH ACQUISITION TO ENHANCE CANCER DRUG PORTFOLIO - FT
- Merck's Acquisition: Merck is set to acquire a biotechnology company for approximately $6 billion to enhance its cancer drug pipeline.
- Strategic Focus: This deal reflects Merck's commitment to expanding its portfolio in oncology and strengthening its position in the competitive cancer treatment market.
See More
U.S.-Iran Negotiations Progress and Meta Verdict
- U.S.-Iran Negotiations: President Trump announced that the U.S. and Iran are currently in negotiations, having sent a 15-point peace plan to Tehran, which has lifted investor sentiment and pushed U.S. stock futures higher despite ongoing war-related uncertainties.
- Meta Verdict Impact: A New Mexico jury found Meta liable for $375 million in damages for failing to protect children from online predators, a ruling that could pressure Meta's financials, with the company stating it will appeal the decision.
- OpenAI Strategic Shift: OpenAI is shutting down its short-form video app Sora, which achieved one million downloads within five days of launch, reflecting the company's cost-cutting measures as it prepares for a potential IPO, while the CFO revealed plans to raise $10 billion in new funding.
- Government Shutdown Agreement Near: Senate Republicans and the White House are close to a deal to end the partial government shutdown, which could stabilize market sentiment, particularly regarding funding for the Department of Homeland Security, although Democrats have yet to express approval.
See More
MERCK & CO INC ANTICIPATES $5.8 BILLION CHARGE OF APPROXIMATELY $2.35 PER SHARE IN Q2 AND FY2026, WITH DEAL CLOSURE EXPECTED IN Q2 2026
Merck & Co. Deal Closure: Merck & Co. is expected to finalize a significant deal in the second quarter of 2026.
Financial Implications: The deal is projected to incur a charge of approximately $2.35 per share in the second quarter and will impact the financial results for the fiscal year 2026.
See More
MERCK & CO INC - TRANSACTION VALUED AT APPROXIMATELY $5.7 BILLION NET OF CASH, REFLECTING A 31% PREMIUM OVER 60-DAY VWAP AS OF MARCH 24, 2026
- Deal Overview: Merck & Co has announced a deal valued at approximately $5.7 billion.
- Premium Details: The deal includes a 31% premium based on the 60-day volume-weighted average price (VWAP) as of March 24, 2026.
See More
Merck & Co Inc Acquires Terns Pharmaceuticals at $53.00 Per Share, Valuing Equity at $6.7 Billion
- Acquisition Announcement: Merck & Co. has announced its intention to acquire Terns Pharmaceuticals for $53.00 per share.
- Valuation Details: The total equity value of the acquisition is estimated at $6.7 billion.
See More
Merck to Purchase Terns Pharmaceuticals, Enhancing Hematology Pipeline with TERN-701, a New Treatment for Chronic Myeloid Leukemia (CML)
Merck's Acquisition: Merck has acquired Terns Pharmaceuticals, Inc. to enhance its hematology pipeline.
Focus on Chronic Myeloid Leukemia: The acquisition includes Terns' novel candidate, TERN-701, which is aimed at treating chronic myeloid leukemia (CML).
See More
MERCK CLOSES IN ON $6BN BIOTECH ACQUISITION TO ENHANCE CANCER DRUG PORTFOLIO - FT
- Merck's Acquisition: Merck is set to acquire a biotechnology company for approximately $6 billion to enhance its cancer drug pipeline.
- Strategic Focus: This deal reflects Merck's commitment to expanding its portfolio in oncology and strengthening its position in the competitive cancer treatment market.
See More
U.S.-Iran Negotiations Progress and Meta Verdict
- U.S.-Iran Negotiations: President Trump announced that the U.S. and Iran are currently in negotiations, having sent a 15-point peace plan to Tehran, which has lifted investor sentiment and pushed U.S. stock futures higher despite ongoing war-related uncertainties.
- Meta Verdict Impact: A New Mexico jury found Meta liable for $375 million in damages for failing to protect children from online predators, a ruling that could pressure Meta's financials, with the company stating it will appeal the decision.
- OpenAI Strategic Shift: OpenAI is shutting down its short-form video app Sora, which achieved one million downloads within five days of launch, reflecting the company's cost-cutting measures as it prepares for a potential IPO, while the CFO revealed plans to raise $10 billion in new funding.
- Government Shutdown Agreement Near: Senate Republicans and the White House are close to a deal to end the partial government shutdown, which could stabilize market sentiment, particularly regarding funding for the Department of Homeland Security, although Democrats have yet to express approval.
See More
